BioPharma Commercialisation Intelligence
AI agents that work on behalf of scientists and pharma leaders — navigating one of the world's most regulated industries to compress time from discovery to commercial return, and maximise every day within the IP protection window.
The Core Thesis
Manufacturing one additional tablet of a drug that took a decade to discover costs virtually nothing. The API, the formulation, the packaging — once the process is established, the marginal unit cost approaches zero.
This means a drug's commercial potential is almost entirely determined by reach and speed — not manufacturing. Every month spent navigating regulatory bureaucracy, every layer of the distribution chain that captures margin, every market entered six months late: these are permanent, unrecoverable losses from the IP window.
The traditional commercialisation system — built for a world before AI, before real-time logistics, before direct-to-patient models — is catastrophically misaligned with the economics of drug innovation.
controltowers.ai is the infrastructure that makes the economics work — within the regulatory framework, not despite it. AI agents that act on behalf of scientists and pharma leaders: accelerating every stage from late-stage trials to global commercial rollout, while holding GDP, GMP, and serialisation compliance as non-negotiable constraints.
The Commercialisation Problem
Getting an approved drug to patients is a fragmented, margin-destroying gauntlet. Whether through hospitals, pharmacy networks, specialty distributors, or direct-to-patient — each channel adds cost, complexity, and time. controltowers.ai operates across all of them, using AI agents to compress the friction without removing the compliance.
The channel isn't the constraint — the operating complexity is. controltowers.ai removes that constraint by running the operational intelligence layer across every commercialisation route, letting your team focus on the science and the strategy.
The Pricing Problem
Pharmaceutical pricing isn't set by the cost of manufacturing — it's determined by a collision of national HTA decisions, insurer formulary politics, reference pricing cascades, and distribution channel structures. The result: a drug that earns €744 net per unit in the US may earn €94 in the UK on the same manufacturing cost. And whether it's reimbursable at all determines whether it reaches patients — regardless of clinical merit. controltowers.ai gives manufacturers the intelligence and operational infrastructure to navigate this, market by market, channel by channel.
A specialty drug listed at €112,000/year in the US may be available in Germany at €14,000 — the same molecule, the same manufacturer. Reference pricing in some markets uses the lowest European price, creating a cascade that can undermine global pricing strategy. Most manufacturers navigate this reactively. CT gives you the intelligence to navigate it proactively.
A drug can be clinically approved and still commercially dead if payers don't reimburse it. In the US, insurer formulary placement, prior auth requirements, and step therapy protocols determine whether patients can actually access it. In Europe, NICE, G-BA, and HAS add further layers of evidence requirements and pricing negotiation. CT maps the reimbursement landscape before launch, not after.
Combine price distortion, reimbursement friction, and distribution channel costs — and the net realisation for the same drug can vary from €68 per €100 (DTP, US commercial insured) to effectively zero (not reimbursed, specialty distributor, small market). These aren't edge cases. They're the rule. CT makes them visible and actionable.
Illustrative example — same drug, different markets
Specialty biologic, moderate-to-severe chronic condition. Fictional drug, real market dynamics.
| Market | List price / year | Reimbursement status | Key gatekeeper | Distribution channel | Distribution cost | Manufacturer net / year | Net margin |
|---|---|---|---|---|---|---|---|
| 🇺🇸United States | €112,000 | Tier 3 — PA req. | Insurer formulary · Prior auth + step therapy · PBM rebate demands | Specialty distributor + specialty pharmacy | –€39,000 (35%) | ~€72,500 | |
| 🇺🇸United States via CT DTP |
€112,000 | Insured + savings card | CT agent handles PA · Savings card covers co-pay · No step therapy delay | CT direct-to-patient | –€11,200 (10%) | ~€100,800 | |
| 🇬🇧United Kingdom | €32,700 | NICE — restricted | NICE TA with access criteria · Patient access scheme · Budget impact negotiation | NHS hospital + pharmacy | –€11,450 (35%) | ~€21,300 | |
| 🇩🇪Germany | €34,000 | G-BA — added benefit | G-BA AMNOG assessment · Negotiated rebate with GKV-SV · Reference price risk | Statutory health insurance + hospital | –€12,240 (36%) | ~€21,760 | |
| 🇫🇷France | €29,000 | HAS — SMR modéré | HAS transparency commission · CEPS price negotiation · Reimbursement rate 65% | Hospital + retail pharmacy | –€11,310 (39%) | ~€17,690 | |
| 🇯🇵Japan | ¥3,200,000 | NHI listed | PMDA + MHLW pricing · Biennial price revision · Volume-based erosion | Hospital + wholesale (wholesaler 97%) | –¥1,280,000 (40%) | ~¥1,920,000 | |
| 🇺🇸United States uninsured / not reimbursed |
€112,000 | Not covered | Patient pays list price · No access for 95%+ · Market effectively closed · Brand damage risk | Specialty pharmacy (self-pay) | –€46,500+ (42%) | ~€0 effective |
¹ Distribution cost includes wholesaler margin, pharmacy margin, PBM rebates, and channel operating costs. Net realisation is illustrative and excludes manufacturing cost, rebates paid directly to payers, and market-specific discounts. Reference: IQVIA, EFPIA, CMS data 2023–24. US specialty biologic distribution costs: Specialty Pharmacy Continuum, 2024.
The US insurer distortion
In the US, private health insurers — not clinical bodies — make the effective access decision. Their tools are formulary placement, prior authorisation (PA), step therapy requirements, and specialty tier co-pays. The result: a drug approved by the FDA may be inaccessible to the majority of patients due to insurer friction, not clinical judgment.
Prior authorisation — insurer requires clinical justification before approving coverage. Average: 3 weeks delay. 17% ultimately denied after appeal.
Step therapy — insurer requires trial of a cheaper drug first. Can add 6–12 months before patient accesses the prescribed medication.
Specialty tier co-pay — patient may owe €1,400–€4,650 per month even when insured. Without a savings card, most patients abandon treatment.
PBM rebate demands — Pharmacy Benefit Managers extract rebates from manufacturers as a condition of formulary placement. The rebate is not passed to the patient.
What controltowers.ai does instead
CT agents run the access and reimbursement layer — across every payer, every market — as an AI-managed operational service. Where an insurer creates friction, CT creates a resolved workflow. The goal is a patient who never experiences the barrier.
PA automated — CT Access Agent generates PA request via CoverMyMeds within minutes of prescription receipt. Appeal letter drafted on denial. Human reviews before submission.
Step therapy bypassed — CT identifies step therapy exceptions, files medical necessity documentation, and tracks appeal deadlines. Reduces patient delay from months to days.
Co-pay zeroed — manufacturer savings card auto-applied at checkout. Patient cost reduced to €0 on most commercial plans. CT manages annual cap tracking and reconciliation.
DTP sidesteps PBM — direct-to-patient model eliminates PBM spread entirely. Revenue flows manufacturer → payer adjudication → CT fulfilment → patient. No rebate extraction.
The Revenue Model
Full pharmaceutical GDP compliance, EU FMD and DSCSA serialisation, temperature excursion monitoring, and audit-ready chain of custody — without building a compliance team.
Patient-centric logistics across 40+ markets, cold chain for biologics, home delivery orchestration, and real-time delivery status — enabling rollout at global scale from day one.
Real-time inventory, demand forecasting, supply disruption alerts, and continuous cost optimisation. The AI agent monitors and acts — you are informed, not burdened.
Business Model
Every drug reaches patients through a chain of intermediaries — each extracting margin. For a €100 drug, a typical hospital or pharmacy route returns only €43–60 to the manufacturer. The rest is absorbed by distributors, wholesalers, PBMs, and pharmacy networks before a single patient sees the product. controltowers.ai changes the architecture.
Global Pricing Reality
A drug approved in the US may cost ten times more than in Germany — yet the manufacturer often nets less after rebates, PBM spread, and insurer leverage. Reimbursability determines whether a drug is commercially viable at all. The complexity of navigating this — market by market, payer by payer, channel by channel — is where commercial launches fail. controltowers.ai maps this and works it.
Net margin by drug type and commercialisation route — the complexity cost is real
The cost-to-commercialise as a percentage of revenue varies dramatically depending on volume (number of patients), complexity (cold chain, rare disease access, prior auth burden), and channel. High-volume simple drugs are squeezed by PBM leverage. Rare disease drugs face astronomical access costs. Both are problems CT can solve.
The insurer problem · US-specific
Health insurers and PBMs extract value from both sides of the transaction
In the US, pharmacy benefit managers (PBMs) negotiate rebates from manufacturers in exchange for formulary placement — then pocket a significant portion rather than passing savings to patients. The result: manufacturers pay rebates of 40–60% of list price, patients still face high co-pays, and PBMs profit from the spread. Prior auth is weaponised as a delay tactic. Step therapy forces patients onto inferior drugs before the prescribed product. Denial rates on specialty drugs can exceed 30%.
How CT changes this
Automate through the friction. Route around the intermediary where possible.
controltowers.ai attacks the insurer problem at every point. For DTP-eligible drugs, CT bypasses the PBM entirely — routing from manufacturer through payer adjudication directly to the patient, eliminating PBM spread and formulary leverage. For non-DTP drugs, CT automates prior auth, handles denials and appeals within hours rather than weeks, and runs step therapy challenges. The manufacturer gains visibility into denial rates, appeal outcomes, and access friction in real time — and CT agents act on it.
What CT does — instead of the distribution stack
Live programmes — as deployed
Chronic Sleep · Schedule IV
SleepPilot 10mg
Insomnia · US · e-Rx via Surescripts
Weight Management · Commercial
WeightPilot 2.5mg / 5mg
Obesity · US · titration programme
Rare Disease · EAP · Named Patient
RarePilot 50mg IV
Ultra-orphan · EAP · GDP cold chain
Operational infrastructure
AI Agents · BioPharma · Regulation-Aware
Your strategic partner from discovery to commercial launch. IP economics, DTP modelling, regulatory acceleration, investor narrative.
Analyses your patent portfolio, identifies lifecycle extension opportunities, and models the revenue impact of each protection strategy.
Maps the fastest compliant route to approval across EMA, FDA, and MHRA — then runs the timeline and resource modelling automatically.
Models your supply chain cost structure, identifies inefficiencies, and builds the business case for DTP transition across your target markets.
Inputs molecule type, patient population, and geography — outputs a full revenue comparison between DTP and traditional distribution channels.
Builds your payer strategy across top markets, models reimbursement timelines, and identifies the evidence requirements for national health system approval.
Platform Architecture · Trust & Compliance
controltowers.ai ingests data from clinical trial management systems, ERP platforms, regulatory dossier repositories, supply chain systems, and real-world evidence sources into a unified, permissioned vault. All data is versioned, timestamped, and immutable once committed — creating an audit-ready foundation that supports both operational decisions and regulatory submissions.
In a regulated pharmaceutical environment, not all users should see all data — and not all AI agent outputs should be acted upon without appropriate authorisation. controltowers.ai enforces granular, role-based access control mapped to the real organisational structure of pharma companies: QP, QA, regulatory, commercial, and supply chain functions each operate within defined data and action boundaries.
Regulatory authorities — EMA, FDA, MHRA — increasingly scrutinise AI-generated outputs used in submissions and supply decisions. controltowers.ai generates a cryptographically signed, immutable audit trail for every agent action: the data accessed, the model version used, the output produced, and the human who acted on it. This is not a log file. It is a legally defensible record.
The use of computerised systems in pharmaceutical manufacturing, quality, and regulatory processes is governed by EMA GMP Annex 11 and FDA 21 CFR Part 11. controltowers.ai is designed for CSV (Computer System Validation) compliance — with documented qualification protocols, risk assessment frameworks, and change control processes built into the platform lifecycle.
controltowers.ai maintains a live Authorisation Register — a governed record of every consequential AI-generated recommendation and the human decision made in response. This is the accountability layer: the record that demonstrates that AI augments human judgement in pharmaceutical decisions rather than replacing it. It is available for regulatory inspection on demand.
Who We Serve
Before & After
Who we are
controltowers.ai is a Service-as-Software platform built to compress the time and capital required to commercialise pharmaceutical drugs. We replace the fragmented stack of consultants, dashboards, and manual processes with AI agents that do the work — running market access strategy, direct-to-patient infrastructure, supply chain operations, and regulatory intelligence in real time.
We work with BioPharma companies who have proven science and need commercial velocity — typically those operating within an IP protection window where every quarter matters.
Early Access
We are onboarding a select group of founding clients. BioPharma companies, research institutions, and pharma-focused investors who want to build the commercialisation advantage now.
Founding clients receive priority onboarding, preferred pricing, and direct input into the agent roadmap.